Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 73

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 73
---
 and others in the medical community.
We may not be able to achieve or maintain market acceptance of our products over time if new products or technology are introduced that
are more favorably received than our products, are more cost effective or render our drug obsolete. We will face competition with respect
to our drug candidates from other pharmaceutical companies developing products in the same disease/therapeutic area and specialty pharmaceutical
and biotechnology companies worldwide. Many of the companies against which we may be competing have significantly greater financial resources
and expertise in research and development, manufacturing, animal testing, conducting clinical trials, obtaining regulatory approvals and
marketing approval for drugs than we do. Physicians, patients and third-party payors may prefer other novel products to ours, which means
that we may not generate significant sales revenues for that product and that product may not become profitable. The degree of market
acceptance of our drug candidates, if approved for commercial sale, will depend on a number of factors, including but not limited to:

| ● | clinical indications for which our drug candidates are approved; |

| ● | physicians, hospitals, and patients considering our drug candidates 
 as a safe and effective treatment;                                  |

| ● | the potential and perceived advantages of our drug candidates 
 over alternative treatments;                                  |

| ● | the prevalence and severity of any side effects; |

| ● | product labeling or product insert requirements of the FDA,          
 NMPA, EMA, Health Canada or other comparable regulatory authorities; |

| ● | limitations or warnings contained in the labeling approved by                 
 the FDA, NMPA, EMA, Health Canada or other comparable regulatory authorities; |

| ● | the timing of market introduction of our drug candidates as 
 well as competitive drugs;                                  |

<div align='center'>38</div>

| ● | the cost of treatment in relation to alternative treatments 
 and their relative benefits;                                |

| ● | the availability of adequate coverage, reimbursement and pricing 
 by third-party payors and government authorities;                |

| ● | lack of experience and financial and other limitations on our                                                                   
 ability to create and sustain effective sales and marketing efforts or ineffectiveness of our sales and marketing partners; and |

| ● | changes in legislative and regulatory requirements that could                                                                        
 prevent or delay regulatory approval of our drug candidates, restrict or regulate post-approval activities and affect our ability to 
 profitably sell any drug candidates for which we obtain regulatory approval.                                                         |

We depend substantially on the success of the drug candidates being researched as our current Lead Projects